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with mild disease. To identify the right patient for 
the right treatment, good predictor is needed.5-10
Antibodies against cyclic citrullinated peptide 
(anti-CCP) are a new and highly specifi c marker for 
RA.2-4 Anti-CCP antibodies are now considered as 
an important serological marker for the diagnosis 
of RA and as a possible prognostic marker for the 
development of erosive disease.8,9 
We investigated the correlation between 
anti-CCP antibodies and the severity of clinical 
manifestation, laboratory manifestation, and 
radiological joint destruction in RA patients in a 
cross sectional study.
METHODS
We included 31 patients with RA fulfi lling the 
ACR criteria for diagnosis.11 All of the patients 
are the outpatients of Rheumatology Clinic of 
Dr. Saiful Anwar General Hospital between April 
2007 and Desember 2008 who had given their 
written informed consent. 
Clinical evaluation of disease was based on 
sex, age, duration of disease, duration of DMARD 
(methotexrate) therapy, BMI, tender joint count, 
swollen joint count, visual analog scale. Disease 
activity was assessed by the 28 joint disease 
activity score (DAS28-3(CRP)).12
The patients had venous blood taken for full 
blood counts, erythrocyte sedimentation rates 
(ESR), renal and liver function, and C-reactive 
protein (CRP). Serum antibodies against cyclic 
citrullinated peptide were analysed using enzyme 
linked immunoadsorbent assay (ELISA). The 
result was expressed in units. The samples were 
considered positive if the antibody titer was 
greater than 20 U/ml. The Ig-M RF was examined 
with ELISA and the result greater than 8 IU/ml 
was regarded as RF positive.
Standardized postero-anterior radiograps 
of right and left hands were performed and 
radiographic damage was scored by one 
rheumatologist who had no information about the 
clinical and laboratory data of each patient using 
Sharp modifi ed score.13 In each case, 14 joints 
were scored for joint erosion and 13 joints were 
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Background. The second generation anti-cyclic 
citrullinated peptide test (CCP2)  displays sensitivity 
comparable to that of rheumatoid factor (RF) 
(approximately 80%) but with superior specifi city 
(98%) . Several observations have indicated that early 
rheumatoid arthritis (RA) patients with positive anti-CCP 
may develop a more erosive disease than those without 
anti-CCP.
Objective. The purpose of this cross-sectional study 
was to investigate the correlation between anti-CCP 
antibodies and clinical and laboratory parameters and 
radiological joint destruction in RA patients.
Methods. We studied 31 patients with RA fulfi lling 
the 1987 revised criteria of American College of 
Rheumatology in Rheumatology Clinic of Saiful Anwar 
General Hospital, Malang, Indonesia. Clinical parameters 
were collected such as age, sex, visual analog scale, 
disease duration and diseases activity score (DAS28-
3(CRP)). Laboratory parameters were WBC, hemoglobin, 
platelet count, erythrocyte sedimentation rate, and C-
reactive protein. Analyzed autoantibody profi les were 
RF and anti-CCP (ELISA methode). Radiological joint 
destruction was evaluated from bilateral postero-anterior 
manus x ray (Sharp score). 
Results. Anti-CCP antibodies were detected in 48.4% 
of RA patients with mean antibody concentration was 
291.24±143.67 (range 16-523.8) units. Anti CCP level 
was signifi cantly correlated with duration of RA (month) 
(p=0.04, r=0.371), RF level (p=0.002, r=0.542) and 
Sharp score (p=0.048, r=0.358), but was not signifi cantly 
correlated with other clinical and laboratory parameters. 
Conclusion. Anti-CCP level was correlated with duration 
of disease, RF, and Sharp score.
Rheumatoid Arthritis (RA) is a systemic 
autoimmune disease affecting about 0.5 - 1% of 
the adult population. The disease is characterized 
by joint infl ammation that can lead to progressive 
joint damage and affect the quality of life.1-4
The course of RA is varied, ranging from 
mild to progressive forms. Availability of better 
prognostic markers would make it possible to 
select predictably severe cases for aggressive 
therapy at an early stage, while at the same time 
avoiding unnecessary exposure to the patients 
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scored for joint space narrowing. Each joint was scored from 
0 to 3 for joint erosion and from 0-4 for joint space narrowing. 
The evaluated joints for joint erosion were interphalangeal 
(IP) I, proximal interphalangeal (PIP) II, PIP III, PIP IV, PIP 
V, metacarpophalangeal (MCP) I, MCP II, MCP III, MCP 
IV, MCP V, proximal of metacarpal I, distal of radius, distal 
of ulna, and multangulum, naviculare, lunatum, triquetrum 
as one joint evaluation. The evaluated joints for joint space 
narrowing were IP I, PIP II, PIP III, PIP IV, PIP V, MCP I, MCP 
II, MCP III, MCP IV, MCP V, proximal of metacarpal III/IV/
V, multangulum/naviculare, lunatum-triquetrum, capitatum-
naviculare-lunatum, and radiocarpal. Sharp score is the total 
sum of grading from joint erosion and joint space narrowing.
Spearman’s correlation coeffi cient expressed the 
correlations between the assessed variables.  Statistical 
signifi cant was defi ned as p value of less than 0.05. All 
analyses were performed using SPSS program version 17 for 
windows.
RESULT
Patients characteristic
Rheumatoid arthritis patients in this study as many as 90.32% 
were female. Female to male ratio was 9:1 and the mean age 
was 51.2 years. The mean disease activity of RA base on 
disease activity score (DAS28-3(CRP)) was 3.18. Rheumatoid 
arthritis patients showing high disease activity was less than 
ones showing low disease activity (table 1). 
Table 1  Patients characteristic 
Patients characteristic n=31
Female (%) 90,32
Age (year) (mean±SD) 51,19±12,03(20-70)
Duration of disease (month) (mean±SD) 56,35±102,64(1-444)
Duration of DMARD therapy (month) (mean±SD) 20,58±16,03(0-60)
BMI (kg/m2) (mean±SD) 21,99±4,02(14,7-32,9)
Tender joint count (TJC) (mean±SD) 7,84±9,64(0-28)
Swollen joint count (SJC) (mean±SD) 4,87±5,65(0-24)
High disease activity (DAS>3,2) (%) 41,90
Low disease activity (DAS≤3,2) (%) 58,10
Ethnic Java (%)
Hand joint arthritis, symmetric joint involvement, and 
morning stiffness were the main signs and symptoms of RA 
that had made patients looked for treatment (table 2).
Table 2  Clinical signs and symtomps in accordance with the 1987 
revised  criteria of American College of Rheumatology
Classifi cation  criteria n Proportion
Morning stiffness  27 87.10%
Hand joint arthritis  29 93.50%
Symmetric joint involvement  28 90.30%
Arthritis ≥ joints simultaneously  13 41.90%
Rheumatoid nodule  0 0%
Rheumatoid factor 18 58.10%
Radiographic changes consistent 
with rheumatoid arthritis
29 93.50%
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Using spearman’s correlation test, Anti CCP level was 
signifi cantly correlated with duration of RA (month), RF 
level, the number of joint erosion, and Sharp score (table 3, 
fi gure 1).  
Table 3  Correlation between anti-CCP level and clinical, laboratory, 
and radiological damage
Variables Correlation*
p r
Age 0.848 0.036
BMI (kg/m2) 0.582 0.103
Duration of RA (month) 0.04 0.371
Duration of therapy 0.268  0.205
Morning stiffnes 0.871 0.031
VAS (mean) 0.906 0.022
DAS (mean) 0.818 0.043
ESR(mm/1st hour) 0.190 0.242
CRP (mg/L) 0.861 0.033
RF (Unit) 0.002 0.542
JSE (0-78) 0.006 0.481
JSN (0-112) 0.236 0.219
Sharp score(0-190) 0.048 0.358
*Spearman’s correlation test; TJC: tender joint count; SJC: swollen joint count; 
VAS: visual analogue scale; DAS: disease activity score; JE: joint erosion; JSN: 
joint space narrowing.
Figure 1  Correlation between serum anti-CCP level and Sharp score 
in rheumatoid arthritis patient
 DISCUSSION
Female to male ratio in this study is higher than the known 
sex ratio (3:1).14 Studies in Indonesia (6:1),15 Malaysia (8:1),16 
Japan (12:1)17 showed a similar sex ratio. The studies in 
population of established RA patients may involved in the 
hight sex ratio as showed in these study. 
The mean age of patients in this study was 51.2 years with 
the mean age of onset was 46.6 years. This is consistent that 
the most RA often occurs in the fourth and fi fth decade, 80% 
of patients got RA at the age of 35-50 years.14
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In this study, anti-CCP antibodies and infl ammation (CRP) 
were correlated with the degree of joint damage assessed by 
Sharp score, but anti-CCP antibodies were not correlated with 
the degree of infl ammation and clinical manifestations. These 
fi nding led to assumption that anti-CCP causes joint damage 
not through the mechanism of infl ammation.  A prospective 
study by Lindqvist et al in 183 early-stage of RA patients, 
showed the role of anti-CCP, IgA, RF, anti-IL1, ESR, CRP, 
and cartilage oligomeric matrix protein in predicting damage 
to the hand and foot joints.9 However, Serdaroglu et al showed 
that there was no signifi cant difference or correlation in DAS, 
VAS, ESR, CRP, duration of disease, radiological damage of 
hands between the anti-CCP positive and anti-CCP negative 
RA groups.18
The important strategy to prevent joint damage in RA is to 
start therapy early in the disease course.19-21 However, disease 
severity varies widely, and it is diffi cult to predict the course 
of the disease in each RA patient. Rheumatoid arthritis can be 
stable for a long time in some patients. The ability for early 
diagnosis and to predict a severe disease outcomes in patients 
with RA becomes very important. Therefore, sensitive and 
specifi c serological tests are needed to predict the development 
of erosive damage.22-24
Most of the study proved that a positive RF is an important 
predictor for joint damage over the years of disease. For the 
long term, RF positivity is associated with an unfavourable 
prognosis.20 It appears that anti-CCP antibodies have prognostic 
relevance similar to RF.2,8,25-30 Vencovsky et al found that anti-
CCP positivity was better than RF at predicting progression 
of Larsen score over two years.31 Also, in a prospective cohort 
study of 242 patients with early RA followed up for three 
years, the anti-CCP antibody results correlated with RF, but 
were better than RF as predictor of a more aggressive disease 
course. Kroot et al in a study of patients with early rheumatoid 
arthritis, found that anti-CCP positive patients at follow up had 
developed more signifi cant radiological damage than patients 
without this antibody.32
We found in this study, the duration of DMARD therapy 
was not correlated with levels of anti-CCP antibodies.  Some 
studies evaluate the correlation of anti-CCP positivity and anti-
CCP levels with therapeutic response. They were generally 
performed on patients who have been diagnosed with RA 
who received DMARD therapy, particularly methotrexate and 
anti-TNF drugs, and showed a low correlation between the 
therapies and anti-CCP level and some indicators of disease 
activity as well.33,34 In the largest study of this type, Ronnelid 
and colleagues followed 379 patients with RA under treatment 
for a total of 5 years. Anti-CCP positivity was reversed in only 
3.9% of patients. There was a small but signifi cant decrease 
in the mean anti-CCP level during the fi rst year of treatment, 
and this decrease correlated with sulfasalazine treatment but 
not with other treatment agents. During the subsequent years 
of follow-up there was no signifi cant change in anti-CCP 
levels, and no correlation between treatment response, disease 
activity, and anti-CCP levels.35 
Our study limitation were using cross sectional study, 
uncontrolled duration of disease as confounding variable and 
less number of samples. Further investigations using cohort 
study, controlling duration of disease as confounding variable 
and involving more number of samples are necessary to show 
the prognostic value of anti-CCP.
CONCLUSION
Anti-CCP level was correlated with duration of disease, RF 
and Sharp score.
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